US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Global Targeted Drug ROS1 Inhibitors for NSCLC Market In 2020, the global Targeted Drug ROS1 Inhibitors for NSCLC market size was xx million US$ and it is expected to reach xx million US$ by the end of 2029, with a CAGR of xx% during 2021-2029. This report focuses on the global Targeted Drug ROS1 Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug ROS1 Inhibitors for NSCLC development in United States, Europe and China. Xalkori(Crizotinib) was the first ALK inhibitor to reach the market in 2011 and has been a solid earner for Pfizer, bringing in $530 million in sales for the company in ALK- and ROS1-positive NSCLC for the year of 2019. Market Segmentation: Global Targeted Drug ROS1 Inhibitors for NSCLC Market Average list price of Crizotinib is USD $18400 (Monthly) Average list price of Lorlatinib is USD $17,500 (Monthly) Average list price of Entrectinib is USD$17,000 (Monthly) Worldwide sales projected to reach a peak at USD $700m. Average list price of Larotrectinib is USD $33,000 (Monthly) Segmentation by Product Type: Breakdown of data from year 2015 to 2020 and forecast until 2029:
Segmentation by Application: Breakdown of data from year 2015 to 2020 and forecast until 2029:
- Entrectinib (Entrectinib peak revenue potential is estimated between $500 million and $1 billion.)
Top Companies & Key Players: Global Targeted Drug ROS1 Inhibitors for NSCLC Market The report offers a detailed analysis of several leading Targeted Drug ROS1 Inhibitors for NSCLC manufacturers including:
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
In August 2020, Roche Registration GmbH received marketing authorization valid throughout the European Union for Rozlytrek which is a cancer medicine. It can be used for treating patients from 12 years of age with solid tumours (cancer growths) that have a genetic abnormality called NTRK gene fusion. Rozlytrek is for use in patients with tumours that have spread nearby or to other parts of the body (metastatic cancer) or when removing the tumour by surgery could cause severe harm. Rozlytrek can also be used for treating adults with advanced non-small-cell lung cancer that has a genetic abnormality called ROS1 gene fusion. It should be used only if the patient has not been treated previously with a medicine that blocks ROS1. Rozlytrek contains the active substance entrectinib. Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as alectinib, ceritinib, and lorlatinib due to a wider range of targets. Key Insights Covered: Global Targeted Drug ROS1 Inhibitors for NSCLC Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Targeted Drug ROS1 Inhibitors for NSCLC industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Targeted Drug ROS1 Inhibitors for NSCLC industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Targeted Drug ROS1 Inhibitors for NSCLC industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Targeted Drug ROS1 Inhibitors for NSCLC industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Targeted Drug ROS1 Inhibitors for NSCLC industry. Research Methodology: Global Targeted Drug ROS1 Inhibitors for NSCLC Market
- Beacon Pharma Limited
- Drug International Limted
- Incepta Pharmaceuticals
- Genentech Inc.
- Loxo Oncology, Inc
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other
Table of Contents 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth Rate by Type (2014-2025) 1.4.2 Crizotinib 1.4.3 Lorlatinib 1.4.4 Entrectinib 1.4.5 Other 1.5 Market by Application 1.5.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Share by Application (2014-2025) 1.5.2 Squamous Cell Carcinoma of NSCLC 1.5.3 Adenocarcinoma of NSCLC 1.5.4 Large Cell Carcinoma of NSCLC 1.6 Study Objectives 1.7 Years Considered2 Global Growth Trends 2.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2.2 Targeted Drug ROS1 Inhibitors for NSCLC Growth Trends by Regions 2.2.1 Targeted Drug | read more...